Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Roll-over-studie for pasienter som har fullført en tidligere Novartis-sponset Sabatolimab (MBG453)-studie og som er bedømt av etterforskeren for å dra nytte av fortsatt behandling med Sabatolimab.

19. september 2026 oppdatert av: Novartis Pharmaceuticals

En åpen, multisenter, rullende studie for pasienter som har fullført en tidligere Novartis-sponset Sabatolimab (MBG453)-studie og som er bedømt av etterforskeren for å dra nytte av fortsatt behandling med Sabatolimab.

This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.

Studieoversikt

Detaljert beskrivelse

This is a multicenter, open label, roll-over study to collect and assess safety of sabatolimab in participants who are treated in current Novartis-sponsored parent studies and who are benefiting from continued study treatment including sabatolimab as judged by the investigator.

There is no conventional screening period in this study as participants are expected to transition directly from treatment on the parent protocol to treatment on this roll-over protocol. Participants who are candidates for the roll-over protocol will be evaluated by the investigator in the parent protocol for eligibility for the roll-over protocol. If eligible, the parent protocol end of treatment visit will be performed and the informed consent for the roll-over protocol will be signed. Participants then continue treatment on this protocol with the next planned dose of sabatolimab as monotherapy or with other combination agent(s).

The treatment with sabatolimab and combination agent(s), as applicable, is continued according to the schedule in the parent study. Adverse events (AEs) will be collected continuously throughout the study and participants will be questioned about adverse events at each visit.

Studietype

Intervensjonell

Registrering (Faktiske)

33

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Novartis Investigative Site
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brasil, 88020-210
        • Novartis Investigative Site
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • Novartis Investigative Site
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Oregon Health Sciences University
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112-0550
        • Huntsman Cancer Institute Univ of Utah
      • Toulouse, Frankrike, 31059
        • Novartis Investigative Site
      • Alexandroupoli, Hellas, 681 00
        • Novartis Investigative Site
      • Pátrai, Hellas, 265 04
        • Novartis Investigative Site
    • BS
      • Brescia, BS, Italia, 25123
        • Novartis Investigative Site
    • FI
      • Florence, FI, Italia, 50134
        • Novartis Investigative Site
    • GE
      • Genova, GE, Italia, 16132
        • Novartis Investigative Site
    • MI
      • Milan, MI, Italia, 20162
        • Novartis Investigative Site
    • RM
      • Roma, RM, Italia, 00133
        • Novartis Investigative Site
      • Fukushima, Japan, 9601295
        • Novartis Investigative Site
      • Tianjin, Kina, 300020
        • Novartis Investigative Site
    • Jilin
      • Changchun, Jilin, Kina, 130021
        • Novartis Investigative Site
      • Kuala Lumpur, Malaysia, 59100
        • Novartis Investigative Site
      • Barcelona, Spania, 08036
        • Novartis Investigative Site
      • Madrid, Spania, 28009
        • Novartis Investigative Site
    • Barcelona
      • Badalona, Barcelona, Spania, 08916
        • Novartis Investigative Site
      • Zurich, Sveits, 8091
        • Novartis Investigative Site
      • Prague, Tsjekkia, 128 08
        • Novartis Investigative Site
      • Izmir, Tyrkia (Türkiye), 35100
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Tyskland, 79106
        • Novartis Investigative Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

12 år til 99 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Participant is currently enrolled in a Novartis-sponsored study with sabatolimab, is being treated with sabatolimab, and has fulfilled all requirements in the parent study.
  2. Participant is currently benefiting from the treatment with sabatolimab as determined by guidelines of the parent protocol and investigator's judgment.
  3. Participant has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
  4. Willingness and ability to comply with scheduled visits, treatment plan and any other study procedures.
  5. Written informed consent obtained prior to enrolling in the roll-over study.

Exclusion Criteria:

  1. Participants in cohorts or treatment groups not receiving sabatolimab in the parent protocol.
  2. Participant has been permanently discontinued from sabatolimab treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.
  3. Participant currently has unresolved toxicities for which sabatolimab dosing has been interrupted in the parent study (participants meeting all other eligibility criteria may be enrolled once toxicities have resolved to allow sabatolimab dosing to resume).
  4. Pregnant or nursing (lactating) women. Where pregnancy is defined as the state of a female after conception confirmed by a positive serum hCG laboratory test and until the termination of gestation.
  5. Participant not willing to comply with the contraception requirements outlined in the exclusion criteria of the parent protocol.
  6. Local access to commercially available sabatolimab for parent protocol indications.

Other protocol-defined Inclusion/Exclusion may apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: sabatolimab + azacitidine

Patients will take sabatolimab 800 mg i.v and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w or sabatolimab 400 mg i.v/q2w and azacitidine 75 mg/m2/d d1-7 s.c. or i.v./q4w.

Solution for intravenous infusion

Andre navn:
  • MBG453

Solution for subcutaneous injection or intravenous infusion

Eksperimentell: sabatolimab + decitabine

Patients will take Sabatolimab 400 mg i.v/q2w and decitabine 20 mg/m2/d d1-5 i.v.

Solution for intravenous infusion

Andre navn:
  • MBG453

Solution for intravenous infusion

Eksperimentell: sabatolimab + venetoclax + azacitidine

Patients will take sabatolimab 200 mg i.v./q2w and venetoclax 400 mg p.o. d1-14/q4wk and azacitidine 75 mg/m2/d d1-7/q4w.

Solution for intravenous infusion

Andre navn:
  • MBG453

Solution for subcutaneous injection or intravenous infusion

Tablet for oral administration

Eksperimentell: sabatolimab + spartalizumab + decitabine

Patients will take sabatolimab 400 mg i.v./q2w and decitabine 20 mg/m2/d d1-5 i.v. and spartalizumab 100 mg i.v/q2w.

Solution for intravenous infusion

Andre navn:
  • MBG453

Solution for intravenous infusion

Solution for intravenous infusion

Andre navn:
  • PDR001
Eksperimentell: sabatolimab + HMA

Patients will take sabatolimab 800 mg and azacitidine 75 mg/m2/d d1-7 or decitabine 20 mg/m2/d d1-5/ all q4w

HMA means hypomethylating agents. Hypomethylating agents are azacitidine and decitabine.

Solution for intravenous infusion

Andre navn:
  • MBG453

Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)

Eksperimentell: sabatolimab

Patients will take sabatolimab 800 mg i.v q4w.

Solution for intravenous infusion

Andre navn:
  • MBG453

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: 5 years

An AE is any untoward medical occurrence (e.g. any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. An AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.

An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria: fatal, life-threatening, results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, may have caused a congenital anomaly/birth defect, requires intervention to prevent permanent impairment or damage.

5 years
Severity of AEs and SAEs
Tidsramme: 5 years

Severity of AEs and SAEs will be measured according to the CTCAE v5.0

5 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Duration of exposure to sabatolimab
Tidsramme: 5 years

The length of time patients will be exposed to sabatolimab and will be reported by treatment groups.

5 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

28. februar 2023

Primær fullføring (Antatt)

14. februar 2028

Studiet fullført (Antatt)

14. februar 2028

Datoer for studieregistrering

Først innsendt

3. januar 2022

Først innsendt som oppfylte QC-kriteriene

20. januar 2022

Først lagt ut (Faktiske)

21. januar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

22. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

19. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere